Belite Bio (BLTE) Company Overview

Profile

Full Name:

Belite Bio, Inc

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

April 29, 2022

Indexes:

Not included

Description:

Belite Bio is a biotechnology company focused on developing innovative treatments for eye diseases and metabolic disorders. They aim to improve patients' quality of life through advanced research and new therapies, particularly in areas like retinitis pigmentosa and other retinal diseases.

Events Calendar

Earnings

Next earnings date:

Mar 12, 2025

Recent quarterly earnings:

Nov 12, 2024

Recent annual earnings:

Mar 12, 2024
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

Jan 21, 25 Benchmark
Buy
Nov 15, 24 Maxim Group
Buy
Nov 13, 24 HC Wainwright & Co.
Buy
Sep 12, 24 HC Wainwright & Co.
Buy
Aug 13, 24 HC Wainwright & Co.
Buy
Aug 13, 24 Benchmark
Buy
Jun 20, 24 Cantor Fitzgerald
Overweight
Jun 13, 24 HC Wainwright & Co.
Buy
May 16, 24 Benchmark
Buy
May 15, 24 HC Wainwright & Co.
Buy

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Price

Market cap

Technical

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Revenue

Profit

EPS

ROA & ROE

EBIT & EBITDA

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

PE Ratio

PB Ratio

PS Ratio

Enterprise value

EV/EBITDA

Financial Health

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Leverage

Risk & Stability

Balance Sheet

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Assets

Equity

Liabilities

Debt

Expenses

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cashflow Activities

Free CashFlow

CAPEX

Institutional Ownership

Belite Bio Announces Registered Direct Offering of $15 Million
Belite Bio Announces Registered Direct Offering of $15 Million
Belite Bio Announces Registered Direct Offering of $15 Million
BLTE
globenewswire.comFebruary 5, 2025

SAN DIEGO, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Belite Bio, Inc ("BLTE" or the "Company") (Nasdaq: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it has entered into a securities purchase agreement with a new, fundamental healthcare investor for the purchase and sale of 258,309 American Depositary Shares (“ADSs”) and warrants to purchase 258,309 ADSs, at a purchase price of $58.07 per ADS and accompanying warrant, pursuant to a registered direct offering, equivalent to today's closing price. The offering is expected to result in gross proceeds of approximately $15 million, before deducting offering expenses, as well as the potential for additional proceeds of approximately $15 million from the exercise of five-year warrants issued in the offering. The closing of the offering is expected to occur on or about February 7, 2025, subject to the satisfaction of customary closing conditions.

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript
BLTE
seekingalpha.comNovember 12, 2024

Belite Bio, Inc. (NASDAQ:BLTE ) Q3 2024 Earnings Conference Call November 12, 2024 4:30 PM ET Company Participants Tom Lin - Chairman and Chief Executive Officer Hendrik Scholl - Chief Medical Officer Nathan Mata - Chief Scientific Officer Hao-Yuan Chuang - Chief Financial Officer Conference Call Participants Basma Radwan - Leerink Partners Jennifer Kim – Cantor Yi Chen - H.C. Wainwright Michael Okunewitch - Maxim Group Operator Hello, and thank you for joining us to discuss Belite Bio's Third Quarter 2024 Financial Results.

Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
Belite Bio to Host Webcast on November 12, 2024, to Discuss Third Quarter 2024 Financial Results
BLTE
globenewswire.comNovember 5, 2024

SAN DIEGO, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Tuesday, November 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the third quarter ended September 30, 2024.

Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
Belite Bio Announces Exercise of Warrants for US$28.75 Million Gross Proceeds
BLTE
globenewswire.comNovember 3, 2024

SAN DIEGO, Nov. 03, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announces the entry into a definitive agreement for the immediate exercise of certain outstanding warrants to purchase up to an aggregate of 651,380 ordinary shares of the Company originally issued in April 2024, at an exercise price of US$44.14 per share. The gross proceeds to the Company from the exercise of the warrants are expected to be approximately US$28.75 million. The Company intends to use the net proceeds from the offering for general corporate purposes.

Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
Belite Bio Announces Appointment of Hendrik P. N. Scholl, MD, MA, as Chief Medical Officer
BLTE
globenewswire.comSeptember 1, 2024

SAN DIEGO, Sept. 01, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that its board of directors has appointed Hendrik P. N. Scholl, MD, MA, as the Chief Medical Officer of the Company, effective immediately. Dr. Scholl is the foremost globally recognized authority on Stargardt disease and age-related macular degeneration (AMD), bringing decades of expertise in treating retinal diseases, including the two key indications targeted by Belite Bio's lead drug candidate, Tinlarebant.

Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
Belite Bio Reports Second Quarter 2024 Financial Results and Provides a Corporate Update
BLTE
globenewswire.comAugust 9, 2024

SAN DIEGO, Aug. 09, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite” or the “Company”), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced its financial results for the second quarter ended June 30, 2024, and provided a general business update.

Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
Belite Bio to Host Webcast on August 12, 2024, to Discuss Second Quarter 2024 Financial Results
BLTE
globenewswire.comAugust 5, 2024

SAN DIEGO, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases that have significant unmet medical needs, today announced that it will host a webcast on Monday, August 12, 2024, at 4:30 p.m. Eastern Time to discuss the Company's financial results and provide a business update for the second quarter ended June 30, 2024.

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript
BLTE
Seeking AlphaMay 14, 2024

Belite Bio, Inc. (NASDAQ:BLTE ) Q1 2024 Earnings Conference Call will be held on May 14, 2024 at 4:30 PM ET. Participants include Tom Lin, Nathan Mata, and Hao-Yuan Chuang. Conference Call Participants are Yi Chen and Basma Radwan. Operator welcomes everyone to the discussion on Belite Bio's First Quarter 2024 Financial Results.

Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
Does Belite Bio (BLTE) Have the Potential to Rally 41.14% as Wall Street Analysts Expect?
BLTE
Zacks Investment ResearchApril 10, 2024

The average price target suggests a potential increase of 41.1% for Belite Bio (BLTE). Although studies show that this metric may not always be reliable, an increase in earnings estimates could indicate a potential upside for the stock in the near future.

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript
BLTE
Seeking AlphaMarch 12, 2024

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

  • 1(current)
  • 2
  • 3
  • 1(current)
  • 2
  • 3

FAQ

  • What is the ticker symbol for Belite Bio?
  • Does Belite Bio pay dividends?
  • What sector is Belite Bio in?
  • What industry is Belite Bio in?
  • What country is Belite Bio based in?
  • When did Belite Bio go public?
  • Is Belite Bio in the S&P 500?
  • Is Belite Bio in the NASDAQ 100?
  • Is Belite Bio in the Dow Jones?
  • When was Belite Bio's last earnings report?
  • When does Belite Bio report earnings?
  • Should I buy Belite Bio stock now?

What is the ticker symbol for Belite Bio?

The ticker symbol for Belite Bio is NASDAQ:BLTE

Does Belite Bio pay dividends?

No, Belite Bio does not pay dividends

What sector is Belite Bio in?

Belite Bio is in the Healthcare sector

What industry is Belite Bio in?

Belite Bio is in the Biotechnology industry

What country is Belite Bio based in?

Belite Bio is headquartered in United States

When did Belite Bio go public?

Belite Bio's initial public offering (IPO) was on April 29, 2022

Is Belite Bio in the S&P 500?

No, Belite Bio is not included in the S&P 500 index

Is Belite Bio in the NASDAQ 100?

No, Belite Bio is not included in the NASDAQ 100 index

Is Belite Bio in the Dow Jones?

No, Belite Bio is not included in the Dow Jones index

When was Belite Bio's last earnings report?

Belite Bio's most recent earnings report was on Nov 12, 2024

When does Belite Bio report earnings?

The next expected earnings date for Belite Bio is Mar 12, 2025

Should I buy Belite Bio stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions